NR 546 Week 6 Exam V3 | NR 546
Advanced Pharmacology
Psychopharmacology for the PMHNP |
Actual Q&A with Rationale (NR546 Week 6
Exam) | Chamberlain University
1. A 10-year-old patient is diagnosed with ADHD. The PMHNP chooses to initiate treatment
with Methylphenidate (Ritalin). Which mechanism of action best describes this medication?
A. It stimulates the release of GABA to reduce neuronal excitability.
B. It acts as a selective serotonin reuptake inhibitor in the prefrontal cortex.
C. It blocks the reuptake of norepinephrine and dopamine via the NET and DAT
transporters.
D. It acts as an antagonist at the alpha-2 adrenergic receptor site.
Answer: C
Rationale: Methylphenidate primarily works by blocking the norepinephrine transporter
(NET) and the dopamine transporter (DAT). This action increases the concentration of
these neurotransmitters in the synaptic cleft, particularly in the prefrontal cortex. By
increasing these levels, the medication helps improve attention, focus, and impulse control
in patients with ADHD.
,2. When prescribing Atomoxetine (Strattera) for ADHD, which of the following is a critical
education point regarding the onset of therapeutic effects?
A. Full therapeutic effects may not be observed for 2 to 4 weeks.
B. The medication will show full clinical benefits within 1 to 2 hours of the first dose.
C. Clinical benefits are only seen when taken on an as-needed basis for specific tasks.
D. The medication only works if taken during the evening hours before sleep.
Answer: A
Rationale: Atomoxetine is a non-stimulant selective norepinephrine reuptake inhibitor
(SNRI) that requires a titration period and time for physiological adaptation. Unlike
stimulants, it does not provide an immediate ‘on’ effect and can take several weeks to reach
steady-state efficacy. Patients should be counseled on patience and adherence to the daily
dosing schedule to achieve optimal symptom management.
3. Which side effect of stimulant medications requires immediate discontinuation and
medical evaluation in a pediatric patient?
A. New onset of chest pain or shortness of breath.
B. Occasional dry mouth and increased thirst.
C. Mild decrease in appetite during lunch hours.
D. Difficulty falling asleep if the dose is taken late in the day.
Answer: A
,Rationale: Stimulants carry a risk of cardiovascular side effects, including increased heart
rate and blood pressure. New-onset chest pain, palpitations, or shortness of breath could
indicate a serious underlying cardiac issue. The FDA requires screening for cardiac history
before initiation, and any emergent cardiac symptoms must be investigated immediately.
4. Guanfacine ER (Intuniv) is often used as an adjunct to stimulants in ADHD treatment. What
is its primary mechanism of action?
A. Histamine H1 receptor agonist.
B. Non-selective beta-blocker.
C. Dopamine D2 receptor antagonist.
D. Selective alpha-2A adrenergic receptor agonist.
Answer: D
Rationale: Guanfacine is a selective alpha-2A agonist that works by strengthening the
prefrontal cortex’s regulation of attention and impulse control. It acts postsynaptically to
improve the ‘signal’ of neurotransmission in the brain. This mechanism is particularly
helpful for reducing hyperactivity and improving emotional regulation when stimulants
alone are insufficient.
5. A patient with Narcolepsy is prescribed Modafinil (Provigil). How does this medication
differ from traditional amphetamine stimulants?
A. It primarily targets the orexin system and has lower sympathomimetic activity.
B. It has a much higher potential for abuse and physical dependence.
, C. It causes significant weight gain and sedation as a primary effect.
D. It is used exclusively for the treatment of insomnia rather than wakefulness.
Answer: A
Rationale: Modafinil is a wake-promoting agent that is chemically distinct from
amphetamines and has a lower affinity for the dopamine transporter. It is thought to
influence the hypothalamus and the orexin/hypocretin system to promote alertness. It
typically results in fewer peripheral side effects like jitteriness and tachycardia compared
to classic stimulants.
6. Which of the following medications is a melatonin receptor agonist used for the treatment
of sleep-onset insomnia?
A. Zolpidem (Ambien)
B. Diphenhydramine (Benadryl)
C. Trazodone (Desyrel)
D. Ramelteon (Rozerem)
Answer: D
Rationale: Ramelteon is a selective agonist at the MT1 and MT2 melatonin receptors in the
suprachiasmatic nucleus. It mimics the effects of endogenous melatonin to regulate the
sleep-wake cycle. Unlike benzodiazepines, it has no affinity for GABA receptors and carries
no risk for abuse or physical dependence.
Advanced Pharmacology
Psychopharmacology for the PMHNP |
Actual Q&A with Rationale (NR546 Week 6
Exam) | Chamberlain University
1. A 10-year-old patient is diagnosed with ADHD. The PMHNP chooses to initiate treatment
with Methylphenidate (Ritalin). Which mechanism of action best describes this medication?
A. It stimulates the release of GABA to reduce neuronal excitability.
B. It acts as a selective serotonin reuptake inhibitor in the prefrontal cortex.
C. It blocks the reuptake of norepinephrine and dopamine via the NET and DAT
transporters.
D. It acts as an antagonist at the alpha-2 adrenergic receptor site.
Answer: C
Rationale: Methylphenidate primarily works by blocking the norepinephrine transporter
(NET) and the dopamine transporter (DAT). This action increases the concentration of
these neurotransmitters in the synaptic cleft, particularly in the prefrontal cortex. By
increasing these levels, the medication helps improve attention, focus, and impulse control
in patients with ADHD.
,2. When prescribing Atomoxetine (Strattera) for ADHD, which of the following is a critical
education point regarding the onset of therapeutic effects?
A. Full therapeutic effects may not be observed for 2 to 4 weeks.
B. The medication will show full clinical benefits within 1 to 2 hours of the first dose.
C. Clinical benefits are only seen when taken on an as-needed basis for specific tasks.
D. The medication only works if taken during the evening hours before sleep.
Answer: A
Rationale: Atomoxetine is a non-stimulant selective norepinephrine reuptake inhibitor
(SNRI) that requires a titration period and time for physiological adaptation. Unlike
stimulants, it does not provide an immediate ‘on’ effect and can take several weeks to reach
steady-state efficacy. Patients should be counseled on patience and adherence to the daily
dosing schedule to achieve optimal symptom management.
3. Which side effect of stimulant medications requires immediate discontinuation and
medical evaluation in a pediatric patient?
A. New onset of chest pain or shortness of breath.
B. Occasional dry mouth and increased thirst.
C. Mild decrease in appetite during lunch hours.
D. Difficulty falling asleep if the dose is taken late in the day.
Answer: A
,Rationale: Stimulants carry a risk of cardiovascular side effects, including increased heart
rate and blood pressure. New-onset chest pain, palpitations, or shortness of breath could
indicate a serious underlying cardiac issue. The FDA requires screening for cardiac history
before initiation, and any emergent cardiac symptoms must be investigated immediately.
4. Guanfacine ER (Intuniv) is often used as an adjunct to stimulants in ADHD treatment. What
is its primary mechanism of action?
A. Histamine H1 receptor agonist.
B. Non-selective beta-blocker.
C. Dopamine D2 receptor antagonist.
D. Selective alpha-2A adrenergic receptor agonist.
Answer: D
Rationale: Guanfacine is a selective alpha-2A agonist that works by strengthening the
prefrontal cortex’s regulation of attention and impulse control. It acts postsynaptically to
improve the ‘signal’ of neurotransmission in the brain. This mechanism is particularly
helpful for reducing hyperactivity and improving emotional regulation when stimulants
alone are insufficient.
5. A patient with Narcolepsy is prescribed Modafinil (Provigil). How does this medication
differ from traditional amphetamine stimulants?
A. It primarily targets the orexin system and has lower sympathomimetic activity.
B. It has a much higher potential for abuse and physical dependence.
, C. It causes significant weight gain and sedation as a primary effect.
D. It is used exclusively for the treatment of insomnia rather than wakefulness.
Answer: A
Rationale: Modafinil is a wake-promoting agent that is chemically distinct from
amphetamines and has a lower affinity for the dopamine transporter. It is thought to
influence the hypothalamus and the orexin/hypocretin system to promote alertness. It
typically results in fewer peripheral side effects like jitteriness and tachycardia compared
to classic stimulants.
6. Which of the following medications is a melatonin receptor agonist used for the treatment
of sleep-onset insomnia?
A. Zolpidem (Ambien)
B. Diphenhydramine (Benadryl)
C. Trazodone (Desyrel)
D. Ramelteon (Rozerem)
Answer: D
Rationale: Ramelteon is a selective agonist at the MT1 and MT2 melatonin receptors in the
suprachiasmatic nucleus. It mimics the effects of endogenous melatonin to regulate the
sleep-wake cycle. Unlike benzodiazepines, it has no affinity for GABA receptors and carries
no risk for abuse or physical dependence.
